World’s first ever dynamic Portal – www.PharmaTechnologyIndex.com on Exclusive Pharmaceutical Technology Industry, is Marching Ahead :

It is irrefutable that today’s market scenario depicts consistent growth rate due to feather touch communications at ease with wider coverage as far as Pharmaceutical & Healthcare industry is concerned.

Company Profile :

Pharma Technology Index.com Pvt. Ltd is a KNS GROUP COMPANY, a leading Media Consultant since 1971, engaged in providing sourcing and information solution with regards to pharmaceutical sector so as to cater in-depth technical details and specifications related any product, searched by health & pharmaceutical industry so that one can conclude smart purchase of a specific product exactly as indented. PharmaTechnologyIndex.com is more than a portal, providing new Insights and Solutions to accelerate Innovation, Productivity, and Growth. It is the first of its kind VORTAL in Pharmaceutical Industry. Though, most of B2B portals do not foresee deliverables as well as meet the needs of customers. PharmaTechnologyIndex.com is designed to source and provide every recipe required by Pharmaceutical & Healthcare Industry. The company is being run by a team of highly experienced professionals with Mr. Ramesh Shah - Chairman, Mr. Arjav Shah – CEO, Dr. (AM) Minesh Choksi – COO and Ms. Keena Shah – CRO as a key management in the field of Pharmaceutical, Healthcare, Machinery, Pharmaceutical Exhibitions and Magazines.

The platform, PharmaTechnologyIndex.com, is, so informative, Interactive and user friendly that one can reach out backward to forward integration without any hassle. This enables access to the remotest vendors almost each and every links on foot rest of Pharma Technology. Rather than depending upon one single vendor, it is a Gateway to many options for better negotiations so as to bring down RMC and manage inventory efficiently. Since the portal is Pharma and its allied industry centric, you have wider scope of reaching out a smallest vendor or buyer globally.

Advantages & Benefits of www.pharmatechnologyindex.com

Ø Meet the pioneers in Pharmaceutical Machinery Manufacturing Technology.

Ø Display Latest Innovations.

Ø Ideal opportunity to Launch New Products.

Ø Gives perspective on Latest Regulatory Developments, Key Indicators & Major Corporate Development.

Ø Exploits the competitive Pharmaceutical market and provides a lead to Future Business Opportunities.

Ø Take advantage of the Strategic Marketing Opportunity.

Ø Gives an insight of the Pharmaceutical market Including New Trends and Technologies in Manufacturing Pharmaceutical Machinery.

Ø Helps to Assess the need to Diversify/Expand Market Range.

Ø Useful in Benchmarking Against Competitors.

Ø Connectivity to Pharma Associations, Institutions as well as Controlling and Certificating bodies.

This is the best place and opportunity to introduce & sell products and services. For visitors the site is a Huge Showcase of the Latest Technology and Products in the world. Potential buyers can find almost anything they need, want and select for their Expansion. A large number of National & International companies will provide the Global overview of this sector with New Innovations and Research Technology that are already on or are in the anvil and will bring together all the key players under one roof, providing advertisers with a compelling networking opportunity – to precisely target relevant budget-holders in the shortest time possible and at an affordable cost. And also showcases the rapidly progressing scenario of the Pharmaceutical Industry. It aims at bringing together world renowned companies as well as newly launched companies on one platform. And together will provide a unique platform to all leading machinery manufacturers and new comers worldwide for launching their Latest Innovations and Technologies. It will also serve as a Gateway for Expanding their markets Worldwide. As well as the rapidly progressing scenario of the pharmaceutical industry. Moreover, it will be the only source for the latest ideas, products and solutions for the entire scope of the pharmaceutical business, presented by advertisers and help Industry professionals accelerate product innovation to establish a first to market advantage in a burgeoning market that holds great Promise & Potential for advancing technologies.

PharmaTechnologyIndex.com is designed to fill the gap by Creating an Environment for the presentation of advances in healthcare Industry achieved through the application of science, technology and best value in products, equipment, works and services. This will be achieved by means of a series of presentations on the vortal by key manufacturers and suppliers. It will also be a platform to build relationships, meet and do business, with new and prospective clients who are looking to Implement Innovation. The platform will provide an excellent platform for service providers to showcase their products and services to decision makers from leading Medical and Pharmaceutical manufacturers. It will offer an unrivalled opportunity worldwide to meet with the who's who of the Industrial world in one place at one time. It is an exciting new networking platform for International Industry players to converge, network and discuss new business alliances and joint ventures. The site will be a preferred destination for the National & International Pharma and Biotech Industries.

The Vortal comprehensively focuses broader spectrum of Pharma Technology Industry as a whole, which includes, Processing Machineries, Packaging Machineries, Packaging Materials, Analytical Intruments, Laboratory Instruments, Laboratory Chemicals, Laboratory Glassware, API’s and Bulk Drugs, Chemicals & Drug Intermediates, Food Colors and Excipients, Clinical and Contract Research, Contract Manufacturing, Project Management Solution, Consultants, Environment Control & Equipment Services, Water Management Solutions, as well as Utility and Maintenance Services.

More and more Manufacturers / OEM’s from all over the world will catch this opportunity to promote their latest equipments and technology. PharmaTechnologyIndex.com aims at bringing together world renowned Legends as well as newly launched companies on one platform. PharmaTechnologyIndex.com, thus, welcomes everyone to visit www.pharmatechnologyindex.com so as to tap the full potential of its access to click away information and experience the power of fullness.

Pharma Technology Index.com Pvt. Ltd
(A KNS GROUP COMPANY)
702, Corporate House, Opp. Dinesh Hall, Income-Tax,
Ashram Road, Ahmedabad – 380 009. India
Telephone # +91-79 27540493/30008999.

Email : This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Aug 11, 2010

US specialty pharmaceutical company Sepracor Inc, owned by Japan's Dainippon Sumitomo Pharma Co since April, and Mumbai-based Generics maker Glenmark   have announced the settlement of their patent dispute over generic Eszopiclone tablets, which Sepracor markets under the brand name Lunesta.

Sepracor entered into a settlement and license agreement with the Glenmark Pharmaceuticals Ltd and its wholly -owned US subsidiary Glenmark Generics Inc, US, under which Glenmark would be permitted to launch its generic product after 30 November 2013, or two and one half months prior to the expiry of Sepracor's US Patent 6,444,673, or 30 May 2014 if Sepracor obtains paediatric exclusivity for Lunesta.

The settlement and license agreement and consent judgement and order also would permit Glenmark to launch its generic product earlier under certain circumstances, which the two companies did not disclose.

The court's approval of the proposed consent judgement and order of permanent injunction would dismiss Sepracor Inc and Glenmark's respective claims and defenses without prejudice in the consolidated litigation currently pending against Glenmark and other defendants.

Lunesta is available in 1mg, 2mg and 3mg tablets and is indicated for the treatment of insomnia.

According to IMS Health data for the 12 month period ending March 2010, Lunesta achieved annual sales of USD 741 million and is the second highest selling branded prescription medication in its class.

Glenmark has settled two patent suits this year, one with GlaxoSmithKline (GSK) concerning atovaquone and proguanil hydrochloride tablets, the generic version of GSK's Malarone tablets use in the treatment of malaria in April

And in May, a patent-infringemnt lawsuit with US drug giant Merck & Co for generic version of its Zetia (ezetimibe.) It reached an out of court deal that allowed Glenmark to launch the drug ahead of Merck's patent cover over it expires.

August 5, 2010

Sudhir Mehta has taken the Torrent Group into ever-newer areas. What started in the early 1970s as Trinity Laboratories has turned into a $1.41 billion global business conglomerate with diversified interests in pharma and power. The company was founded by the late U N.

The 1954-born Sudhir Mehta consolidated the initial success of the company and put the emphasis on exports. He also initiated the diversification of the Torrent Group into the power sector, and made Torrent Pharma one of India’s biggest exporters of pharma products. He took office as the Chairman of the Torrent conglomerate in April 1998.

Displaying an astute entrepreneurial mind and an appetite for calculated risks, Mehta forayed into the turbulent Russian market at a time when the region was embroiled in deep political turmoil. Today, Torrent Pharma has a strong presence in the European countries, Russia and Brazil. Sudhir and his brother Samir Mehta have added to the assets of the company by establishing another pharma plant at Chattral, apart from commissioning a Penicillin G plant.

Flush with funds from the success of Torrent Pharma in the Soviet Union, Mehta decided to diversify into the power sector in the late 1980s. His first move was to acquire a company that manufactures power cables (now called Torrent Cables Ltd.).

In 1991, the Central government announced major policy changes enabling the Indian private sector to enter the power sector. Around this time, Sudhir quietly started acquiring shares of the then Ahmedabad Electricity Company Ltd and Surat Electricity Co. Ltd., gaining a controlling stake in both by the late 1990s.

Simultaneously, he announced plans to set up a 655 Mw dual fuel combined cycle power project in Gujarat. He commissioned the project within the budgeted schedule and cost, and then proposed setting up the 1,147.5 Mw Sugen gas-fired power station, which was recently dedicated to the nation. It is the largest gas-based power project of an independent power producer.

Today the Torrent Group has a strong presence throughout the entire power sector value chain — generation, transmission and distribution. Torrent Power has a total generation capacity of 1650 Mw and plans are afoot to add an additional 6,000-8,000 Mw generation capacity. It distributes power to over 2 million customers in the cities of Ahmedabad, Gandhinagar and Surat in Gujarat and in Bhiwandi in Maharashtra. Torrent Power has also been awarded the distribution franchise for Agra and Kanpur in Uttar Pradesh.

Sudhir and Samir of recently made their maiden entry in the Forbes India Rich List. They have a net worth of $2.02 billion and are at number 23 in the list of the 100 richest Indians.

August 5, 2010

The parliamentary standing committee on health has asked the government to pay attention to the selling out of major Indian Pharma companies to multinationals, whose increasing hold over the drug market it says will make essential medicines costlier.

The committee in its report presented to the Rajya Sabha on Wednesday noted that a large number of pharma companies have sold majority of their shares to multinational companies.

'Promoters of some Indian pharma companies like Piramal Healthcare, Ranbaxy, Shantha Biotech and Dabur Pharma have already sold their controlling shares to US, Japanese and German MNCs,' said the report.

It asked the government to ensure that major Indian pharma companies remain in Indian hands.

'The committee would appreciate if the ministry of health and family welfare takes up the issue with the ministry of chemical and fertilizers without any delay and come up with policy option to ensure that major Indian pharma companies are in Indian hands,' it said.

Pointing out that 61 drugs worth over $80 billion are going off patent between 2011 and 2013 making it possible for domestic pharma companies to produce cheaper version of the drug, the committee expressed concern over the increasing hold of MNCs.

'These developments would result in MNCs gaining market supremacy and essential medicines are bound to be costlier,' it added.

According to the health ministry, India is the third largest producer of generic drugs in the world and exports medicines to nearly 156 countries.